Kumar P, Johnson M, Molina JM, Rizzardini G, et al. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr 2021 Feb 17. pii: 00126334-900000000-95929.
PMID: 33633036